Immunoglobulin replacement therapy for the management of hypogammaglobulinemia and secondary immunodeficiency following B-cell targeted therapies in patients with autoimmune diseases: A systematic-narrative hybrid review.
文献摘要
This systematic-narrative hybrid review assessed evidence on immunoglobulin replacement therapy (IgRT) use in patients with autoimmune diseases who develop hypogammaglobulinemia and/or secondary immunodeficiency following B-cell targeted therapies (BCTT). This work builds upon a 2019 review in patients with rheumatic diseases, and informed consensus recommendations developed through a separate Delphi process. A systematic search identified literature published between 01/09/2018 (2019 review cut-off) and 27/09/2024 (present review search) in PubMed, Web of Science and Cochrane library databases, supplemented by a search for relevant guidelines. Overall, 186 studies and 154 guideline documents were identified. Evidence was synthesized across 17 core research themes. While most core themes were well represented, evidence remained limited in some areas. Despite advances in understanding and clinical practice since 2019, many similar evidence gaps remain, highlighting the need for more structured guidance on management of hypogammaglobulinemia in patients with autoimmune disorders receiving BCTT, including clear criteria for IgRT use.